Description

Charles River’s Recovery Signal: Organic Growth Returns After Nearly Three Years!

Charles River Laboratories reported second quarter 2026 results characterized by modest organic revenue growth and improvements in operating margins, reflecting early signs of recovery in the biopharmaceutical demand environment. The company’s total organic revenue increased by 0.1%, marking the first organic growth since late 2023, driven mainly by a 0.2% organic increase in the Drug Safety Assessment (DSA) segment and a 1.3% rise in Manufacturing revenues. Demand from the DSA segment, especially within nonclinical safety studies, showed strengthening, supported by higher net bookings and a backlog increase, indicating improving client activity, particularly among small and midsized biotech companies as well as global biopharmaceutical clients. The Research Models and Services (RMS) segment experienced a 1.4% organic decline, primarily due to lower volumes in North America, partly offset by stronger demand in China. Operating margin improved notably by 420 basis points sequentially to 20.